Gemini Therapeutics Inc

-0.23 (-4.84%)
Products, Regulatory

Gemini Therapeutics Announces Data Ongoing Phase 2A Study Of Gem103 To Treat Age-Related Macular Degeneration

Published: 06/22/2021 20:16 GMT
Gemini Therapeutics Inc (GMTX) - Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of Gem103 in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Gemini Therapeutics Inc - Gem103 Continues to Be Well-tolerated and Demonstrates a Differentiated Safety Profile.
Gemini Therapeutics Inc - Biomarker Results Indicate Gem103's Ability to Regulate Complement and Complement Factor H Therapeutic Approach.
Gemini Therapeutics Inc - Visual Acuity Remained Stable (±5 Edtrs Letters) Throughout Study.
Gemini Therapeutics Inc - Gem103 Program for Ga Advancing in Discussions With Regulators to Seek Alignment on Late-stage Trial Design.